Chemical Component Summary

NameVancomycin
Identifiersn/a
FormulaC66 H75 Cl2 N9 O24
Molecular Weight1,449.254
TypePEPTIDE-LIKE
Isomeric SMILESC[C@H]1[C@H]([C@@](C[C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2Oc3c4cc5cc3Oc6ccc(cc6Cl)[C@H]([C@H](C(=O)N[C@H](C(=O)N[C@H]5C(=O)N[C@@H]7c8ccc(c(c8)-c9c(cc(cc9O)O)[C@H](NC(=O)[C@H]([C@@H](c1ccc(c(c1)Cl)O4)O)NC7=O)C(=O)O)O)CC(=O)N)NC(=O)[C@@H](CC(C)C)NC)O)CO)O)O)(C)N)O
InChIInChI=1S/C66H75Cl2N9O24/c1-23(2)12-34(71-5)58(88)76-49-51(83)26-7-10-38(32(67)14-26)97-40-16-28-17-41(55(40)101-65-56(54(86)53(85)42(22-78)99-65)100-44-21-66(4,70)57(87)24(3)96-44)98-39-11-8-27(15-33(39)68)52(84)50-63(93)75-48(64(94)95)31-18-29(79)19-37(81)45(31)30-13-25(6-9-36(30)80)46(60(90)77-50)74-61(91)47(28)73-59(89)35(20-43(69)82)72-62(49)92/h6-11,13-19,23-24,34-35,42,44,46-54,56-57,65,71,78-81,83-87H,12,20-22,70H2,1-5H3,(H2,69,82)(H,72,92)(H,73,89)(H,74,91)(H,75,93)(H,76,88)(H,77,90)(H,94,95)/t24-,34+,35-,42+,44-,46+,47+,48-,49+,50-,51+,52+,53+,54-,56+,57+,65-,66-/m0/s1
InChIKeyMYPYJXKWCTUITO-LYRMYLQWSA-N
CompositionPolymer Sequences: MLU-OMZ-ASN-GHP-GHP-OMY-3FG-BGC-RER
BIRD classANTIBIOTIC
Represented AsPOLYMER
Compound Detailsn/a
Descriptionn/a

Chemical Details

Formal Charge0
Atom Count176
Chiral Atom Count18
Bond Count185
Aromatic Bond Count30

Drug Info: DrugBank

DrugBank IDDB00512 
NameVancomycin
Groups approved
DescriptionAntibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to ristocetin that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear. As of January 29 2018, CutisPharma's Firvanq is the only FDA approved vancomycin oral liquid treatment option available for the the treatment of _Clostridium difficile_ associated diarrhea and enterocolitis caused by _Staphylococcus aureus_, including methicillin-resistant strains [LP1196]. Such an oral liquid formulation is expected to make _Clostridium difficile_ associated diarrhea therapy more accessible in comparison to previously available specialty compounding products [LP1196].
Synonyms
  • Vancomycin
  • Vancomycin hydrochloride
  • Vancomycinum
  • Vancomicina
  • Vancomycine
Brand Names
  • Sterile Vancomycin HCl 5.0gm/vial
  • Vancomycin Hydrochloride
  • Sterile Vancomycin Hydrochloride
  • Vancomycin HCl
  • Vancocin
IndicationAdministered intravenously, vancomycin is indicated in adult and pediatric patients for the treatment of septicemia, infective endocarditis, skin and skin structure infections, bone infections, and lower respiratory tract infections.[L41529] Administered orally, vancomycin is indicated in adult and pediatric patients for the treatment of _Clostridium difficile_-associated diarrhea and for enterocolitis caused by _Staphylococcus aureus_ (including methicillin-resistant strains).[L41534]
Categories
  • Agents that produce neuromuscular block (indirect)
  • Alimentary Tract and Metabolism
  • Amino Acids, Peptides, and Proteins
  • Anti-Bacterial Agents
  • Anti-Infective Agents
ATC-Code
  • J01XA01
  • A07AA09
  • S01AA28
CAS number1404-90-6

Drug Targets

NameTarget SequencePharmacological ActionActions
D-Ala-D-Ala moiety of NAM/NAG peptide subunits of peptidoglycan-unknownligand
Serum albuminMKWVTFISLLFLFSSAYSRGVFRRDAHKSEVAHRFKDLGEENFKALVLIA...unknownsubstrate
alpha1-acid glycoproteinMALSWVLTVLSLLPLLEAQIPLCANLVPVPITNATLDQITGKWFYIASAF...unknownsubstrate
Histamine H1 receptorMSLPNTSSASEDKMCEGNRTAMASPQLLPLVVVLSSISLVTVGLNLLVLY...unknownsubstrate
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682

Related Resource References

Resource NameReference
Pharos CHEMBL262777
PubChem 14969
ChEMBL CHEMBL262777
ChEBI CHEBI:28001